The role of methallothioneins in experimental autoimmune encephalomyelitis and multiple sclerosis

Annals of the New York Academy of Sciences

Volumn 1051, Issue , 2005, Pages 88-96

  Espejo, Carmen ^a   Martínez Cáceres, Eva M ^b  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b FUNDACIÓ INSTITUT D INVESTIGACIÓ EN CIÈNCIES DE LA SALUT GERMANS TRIAS I PUJOL   (Spain)

Author keywords

Antioxidant; Experimental autoimmune encephalomyelitis; Metallothionein; Multiple sclerosis; Oxidative stress

Indexed keywords

ALPHA TOCOPHEROL; AMYLOID PRECURSOR PROTEIN; ANTIOXIDANT; BILIRUBIN; CAFFEIC ACID PHENETHYL ESTER; CD4 ANTIGEN; GAMMA INTERFERON; GAMMA INTERFERON RECEPTOR; GLUCOCORTICOID; GLUTATHIONE PEROXIDASE; HEAVY METAL; INTERLEUKIN 1BETA; INTERLEUKIN 6; ISOPROTEIN; METALLOTHIONEIN; METALLOTHIONEIN I; METALLOTHIONEIN II; METALLOTHIONEIN III; NITRIC OXIDE; PEROXYNITRITE; POLYPEPTIDE; PROTEIN; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; SCAVENGER; THYMOQUINONE; TUMOR NECROSIS FACTOR ALPHA; UBIQUINONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; URIC ACID;

ALLERGIC ENCEPHALOMYELITIS; ANTIOXIDANT ACTIVITY; APOPTOSIS; AXONAL INJURY; BRAIN CELL; CELL INFILTRATION; CELL PROTECTION; CHRONIC INFLAMMATION; CONFERENCE PAPER; CYTOPATHOGENIC EFFECT; DEMYELINATING DISEASE; DEMYELINATION; HUMAN; INFLAMMATORY CELL; METAL BINDING; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; TISSUE REPAIR;

EID: 25444442303     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1361.049     Document Type: Conference Paper

References (41)

1. LASSMANN, H. 1999. The pathology of multiple sclerosis and its evolution. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 354: 1635-1640.
2. FERGUSON, B., M.K. MATYSZAK, M.M. ESIRI & V.H. PERRY. 1997. Axonal damage in acute multiple sclerosis lesion. Brain 120: 393-399.
3. MARTIN, R., H.F. MCFARLAND & D.E. MCFARLIN. 1992. Immunological aspects of demyelinating diseases. Annu. Rev. Immunol. 10: 153-187.
4. DE GROOT, C.J., S.R. RUULS, J.W. THEEUWES, et al. 1997. Immunocytochemical characterization of the expression of inducible and constitutive isoforms of nitric oxide synthase in demyelinating multiple sclerosis lesions. J. Neuropathol. Exp. Neurol. 56: 10-20.
5. CROSS, A.H., P.T. MANNING, R.M. KEELING, et al. 1998. Peroxynitrite formation within the central nervous system in active multiple sclerosis. J. Neuroimmunol. 88: 45-56.
6. VLADIMIROVA, O., J. O'CONNOR, A. CAHILL, et al. 1998. Oxidative damage to DNA in plaques of MS brains. Mult. Scler. 4: 413-418.
7. GILGUN-SHERKI, Y., E. MELAMED & D. OFFEN. 2004. The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy. J. Neurol. 251: 261-268.
8. HALLIWELL, B. 1992. Reactive oxygen species and the central nervous system. J. Neurochem. 59: 1609-1623.
9. PENTREATH V.W. & N.D. SLAMON. 2000. Astrocyte phenotype and prevention against oxidative damage in neurotoxicity. Hum. Exp. Toxicol. 19: 641-649.
10. HOOPER, D.C., S. SPITSIN, R.B. KEAN, et al. 1998. Uric acid, a natural scavenger of peroxynitrite, in experimental allergic encephalomyelitis and multiple slerosis. Proc. Natl. Acad. Sci. USA 94: 2528-2533.
11. LIU, Y., B. ZHU, X. WANG, et al. 2003. Bilirubin as a potent antioxidant suppresses experimental autoimmune encephalomyelitis: implications for the role of oxidative stress in the development of multiple sclerosis. J. Neuroimmunol. 139: 27-35.
12. MOHAMED, A., A. SHOKER, F. BENDJELLOUL, et al. 2003. Improvement of EAE by thymoquinone, an oxidative stress inhibitor. Biomed. Sci. Instrum. 39: 440-445.
13. ILHAN, A., O. AKYOL, A. GUREL, et al. 2004. Protective effects of caffeic acid phenethyl ester against experimental allergic encephalomyelitis-induced oxidative stress in rats. Free Radic. Biol. Med. 37: 386-394.
14. SYBURRA, C. & S. PASSI. 1999. Oxidative stress in patients with multiple sclerosis. Ukr. Biokhim. Zh. 71: 112-115.
15. BINZ, P.A. & J.H.R. KAGI. 1999. Metallothionein: molecular evolution and classification. In Metallothionein IV. C. D. Klaasen, Ed.: 7-13. Birkhauser Verlag. Basel.
16. SAMSON, S.L. & L. GEDAMU. 1998. Molecular analyses of metallothionein gene regulation. Prog. Nucleic Acid Res. Mol. Biol. 59: 257-288.
17. YAGLE, M.K. & R.D. PALMITER. 1985. Coordinate regulation of mouse metallothionein I and II genes by heavy metals and glucocorticoids. Mol. Cell Biol. 5: 291-294.
18. UCHIDA, Y., K. TAKIO, K. TITANI, et al. 1991. The growth inhibitory factor that is deficient in the Alzheimer's disease brain is a 68 amino acid metallothionein-like protein. Neuron 7: 337-347.
19. PALMITER, R.D., S.D FINDLEY, T.E. WHITMORE & D.M. DURNAM. 1992. MTs-III, a brain-specific member of the metallothionein gene family. Proc. Natl. Acad. Sci. USA 89: 6333-6337.
20. SHIRAGA, H., R.F. PFEIFFER & M. EBADI. 1993. The effects of 6-hydroxydopamine and oxidative stress on the level of brain metallothionein. Neurochem. Int. 23: 561-566.
21. HIDALGO J., M. ASCHNER, P. ZATTA & M. VASAK. 2001. Roles of the metallothionein family of proteins in the central nervous system. Brain Res. Bull. 55: 133-145.
22. ADLARD P.A., A.K. WEST & J.C. VICKERS. 1998. Increased density of metallothionein I/II-immunopositive cortical glial cells in the early stages of Alzheimer's disease. Neurobiol. Dis. 5: 349-356.
23. EBADI, M., P.L. IVERSEN, R. HAO, et al. 1995. Expression and regulation of brain metallothionein. Neurochem. Int. 27: 1-22.
24. SOGAWA C.A., M. ASANUMA, N. SOGAWA, et al. 2001. Localization, regulation, and function of metallothionein-III/Growth inhibitory factor in the brain. Acta Med. Okayama 55: 1-9.
25. ESPEJO, C., J. CARRASCO, J. HIDALGO, et al. 2001. Differential expression of metallothioneins in the CNS of mice with experimental autoimmune encephalomyelitis. Neuroscience 105: 1055-1065.
26. BROCKE, S., K. GIJBELS & L. STEINMAN. 1994. Autoimmune Disease Models: A Guidebook. I. R Cohen & A. Miller, Eds.: 1-14. Academic Press. San Diego, CA.
27. HIDALGO J., B. CASTELLANO & I.L. CAMPBELL. 1997. Regulation of brain metallothioneins. Curr. Top. Neurochem. 1: 1-26.
28. ESPEJO, C., M. PENKOWA, M. DEMESTRE, et al. 2005. Time course expression of CNS-inflammatory, neurodegenerative, tissue repair markers, and metallothioneins during experimental autoimmune encephalomyelitis. Neuroscience 132: 1135-1149.
29. PENKOWA, M., C. ESPEJO, E.M. MARTÍNEZ-CÁCERES, et al. 2001. Altered inflammatory response and increased neurodegeneration in metallothionein I+II deficient mice during experimental autoimmune encephalomyelitis. J. Neuroimmunol. 119: 248-260.
30. PENKOWA, M., C. ESPEJO, E.M. MARTÍNEZ-CÁCERES, et al. 2003. Increased demyelination and axonal damage in metallothionein I+II deficient mice during experimental autoimmune encephalomyelitis. Cell. Mol. Life Sci. 60: 185-197.
31. VAN LOOKEREN-CAMPAGNE, M., H. THIBODEAUX, N. VAN BRUGGEN, et al. 1999. Evidence for a protective role of metallothionein-1 in focal cerebral ischemia. Proc. Natl. Acad. Sci. USA 96: 12870-12875.
32. TRENDELENBURG, G., K. PRASS, J. PRILLER, et al. 2002. Serial analysis of gene expression identifies metallothionein-II as major neuroprotective gene in mouse focal cerebral ischemia. J. Neurosci. 22: 5879-5888.
33. PENKOWA, M., J. CARRASCO, M. GIRALT, et al. 1999. CNS wound healing is severely depressed in metallothionein I- and II-deficient mice. J. Neurosci. 19: 2535-2545.
34. PENKOWA, M., J. CARRASCO, M. GIRALT, et al. 2000. Altered central nervous system cytokine-growth factor expression profiles and angiogenesis in metallothionein-I+II deficient mice. J. Cereb. Blood Flow Metab. 20: 1174-1189.
35. PENKOWA M., C. ESPEJO, A. ORTEGA-AZNAR, et al. 2003. Metallothionein expression in the central nervous system of multiple sclerosis patients. Cell. Mol. Life Sci. 60: 1258-1266.
36. LOCK, C., G. HERMANS, R. PEDOTTI, et al. 2002. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat. Med. 8: 500-508.
37. SAKURAI, A., S. HARA, N. OKANO, et al. 1999. Regulatory role of metallothionein in NF-kappaB activation. FEBS Lett. 455: 55-58.
38. EL REFAEY, H., M. EBADI, C.A. KUSZYNSKI, et al. 1997. Identification of metallothionein receptors in human astrocytes. Neurosci. Lett. 231: 131-134.
39. CANPOLAT, E. & M.A. LYNES. 2001. In vivo manipulation of endogenous metallothionein with a monoclonal antibody enhances a T-dependent humoral immune response. Toxicol. Sci. 62: 61-70.
40. PENKOWA, M. & J. HIDALGO. 2003. Treatment with metallothionein prevents demyelination and axonal damage and increases olygodendrocyte precursors and tissue repair during experimental autoimmune encephalomyelitis. J. Neurosci. Res. 72: 574-586.
41. YOUN J., S.H. HWANG, Z.Y. RYOO, et al. 2002. Metallothionein suppresses collagen-induced arthritis via induction of TGF-beta and downregulation of proinflammatory mediators. Clin. Exp. Immunol. 129: 232-239.